Harvest fluid is the first evaluable node in viral vector production and the stage with the highest probability of detecting adventitious contaminants. The most common root causes of IND delays occur here: failure to detect rcAAV/RCL, missed mycoplasma contamination, or abnormal bioburden leading to batch rejection. Traditional pharmacopoeial methods conflict with CGT timelines, while poorly validated rapid methods risk regulatory deficiencies.
If contamination is not detected at this stage, it propagates downstream – causing equipment contamination, cross-batch risk, and facility shutdown. Although rcAAV formation is a low-probability event, its presence violates the safety premise of replication-defective vectors; FDA guidance explicitly recommends screening at the harvest fluid stage. Mycoplasma (0.1–0.2 μm) is difficult to remove by conventional filtration and requires a targeted testing strategy.
Creative Biogene provides a complete upstream safety testing solution – from harvest fluid through unpurified bulk. Leveraging validated rapid methods, we align testing depth with your project stage via Core, Advanced, or Rapid packages.
| Project Stage | Recommended Package | Key Inclusions |
| Early R&D / Process development | Rapid Release | Parallel-validated rapid methods (qPCR mycoplasma ≤8 days, qPCR-based virus detection) for rapid results to guide process optimization and in-process monitoring. |
| Pre-IND submission | Advanced Release | Full viral safety testing: bioburden, mycoplasma, endotoxin trend, rcAAV/rcLV/rcRV detection, virus-like particles, and adventitious agent screening, plus an IND-ready report format. |
| Commercial manufacturing | Core Release | Routine release testing: bioburden, endotoxin trend monitoring, mycoplasma testing. Suitable for established, stable processes. |
For Rapid Release: qPCR-based rapid methods are validated in parallel with pharmacopoeial methods. Final product release for clinical use requires compendial testing where applicable.
Test Matrix
| Testing Item | Core Release | Advanced Release | Rapid Release |
| Bioburden | ✓ | ✓ | ✓ |
| Endotoxin (trend monitoring) | ✓ | ✓ | ✓ |
| Mycoplasma (pharmacopoeial culture) | ✓ | ✓ | — |
| Mycoplasma rapid (hybrid PCR) | — | ✓ (parallel validated) | ✓ (accelerated) |
| rcAAV / rcLV / rcRV | — | ✓ (serial passage / qPCR) | — |
| Virus-like particles & TEM | — | ✓ | — |
| Adventitious agent in vitro co-culture | — | ✓ | — |
For specific test panels, method parameters, or pricing, please contact our technical team.
1. Compliance Framework
Built on ICH Q5A(R2) and FDA CMC guidance (2020), with GLP/cGMP dual compliance operation. Data management follows ALCOA+ principles and 21 CFR Part 11, with full LIMS traceability and independent QA review per batch.
2. Method Validation
Pharmacopoeial methods (bioburden, mycoplasma culture, endotoxin) are qualified for applicability. Non-pharmacopoeial rapid methods (qPCR mycoplasma, cell culture-based rcAAV detection) are validated in parallel with pharmacopoeial methods, with complete validation reports provided to ensure data acceptability for IND submission.
3. Environmental Control
Physical segregation and unidirectional workflow separate sample handling, cell culture, and molecular detection, with dedicated biosafety cabinets and HEPA filtration. Dedicated areas and independent culture systems for phage and adventitious virus, with periodic environmental monitoring to prevent cross-contamination.
4. Submission-Ready Reporting
Reports are designed with IND/BLA submission as the endpoint, including method descriptions, raw data, and compliance statements – ready for direct inclusion in the "batch release testing" and "in-process control testing" sections of CMC documentation.
Gel clot or kinetic chromogenic method per USP <85>. Applied for endotoxin trend analysis and process control (not a mandatory release test at this stage).
Culture method per USP <63> with 28-day observation. Suitable for GMP release when time allows.
TEM for morphological assessment; co-culture on indicator cell lines per ICH Q5A(R2) Section 3.2 for non-specific virus screening in harvest fluid.
Select the appropriate test based on the vector type.
If you are preparing a harvest fluid testing strategy for viral vector production or have uncertainties at critical decision points, now is the best time to front load risks and validate proactively. We will systematically design a testing strategy and method combination tailored to your vector type (AAV/LV/RV), cell line background, and project stage – ensuring every decision is supported by robust data, enhancing release certainty and controllability from the source. Contact us today to request your customized harvest fluid testing plan.
Q1: Is rcAAV testing mandatory at the harvest fluid stage for my CGT product?
A: Yes. FDA CMC guidance (2020) explicitly recommends testing for replication competent AAV (rcAAV) at an appropriate stage for replication defective AAV vector products. Harvest fluid is the optimal node – vector concentration is highest, and contaminant detection probability is greatest. We recommend performing rcAAV testing on at least one production batch before IND submission as core data for vector safety.
Q2: Can all required tests be performed on a small volume of harvest fluid?
A: Different tests have different volume requirements. Bioburden and mycoplasma testing typically require 10-50 mL; rcAAV testing requires an additional sample for cell passages. Our technical team can assess testing feasibility and priorities based on your sample volume and, if necessary, propose a reduced testing strategy with appropriate data limitation notes. We recommend discussing sample volume requirements in advance.
Q3: What testing data should I prepare for the IND submission from the harvest fluid stage?
A: For IND submission, we recommend at least the following at the harvest fluid stage: bioburden (batch data), mycoplasma testing, endotoxin trend data, and rcAAV testing. These data should include method validation reports, raw data, and compliance statements. The report format provided with our Advanced package is ready for direct inclusion in CMC files.
Q4: How does the sensitivity of hybrid PCR mycoplasma detection compare with the pharmacopoeial culture method?
A: USP <63> requires that a PCR method, if used as a replacement for the pharmacopoeial culture method, must be validated to achieve a detection limit of ≤10 CFU/mL. Hybrid PCR incorporates a 3-day enrichment culture to minimize matrix interference and improve sensitivity. Studies in CAR-T cell products have demonstrated their ability to detect four mycoplasma species, including the traditionally non-cultivable M. hyorhinis DBS, with results comparable to USP <63>. We recommend parallel validation of the rapid PCR method with the pharmacopoeial method to provide dual assurance for IND submission.
Q5: How do I establish an endotoxin "trend monitoring" strategy for harvest fluid?
A: USP <85> specifies the technical methods for endotoxin testing. Endotoxin testing at the harvest fluid stage is not a mandatory release test, but establishing a trend monitoring strategy helps detect contamination risks early. This includes: setting process control limits based on historical data, defining testing frequency, and defining action limits and alert limits that trigger investigation. We can assist in establishing an endotoxin database and trend analysis model to support process robustness assessment.
Copyright © 2026 Creative Biogene. All rights reserved.